Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 2015-2022

  Moos, Verena ^a   Kunkel, Désirée ^a   Marth, Thomas ^b   Feurle, Gerhard E ^c   LaScola, Bernard ^d   Ignatius, Ralf ^a   Zeitz, Martin ^a   Schneider, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Josefs Krankenhaus   (Germany)

^c Institute Springe   (Germany)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; MEROPENEM; PANTOPRAZOLE; PENICILLIN DERIVATIVE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DUODENUM BIOPSY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTESTINE LIPODYSTROPHY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STOMACH ULCER; TH1 CELL; TREATMENT OUTCOME; TROPHERYMA WHIPPELII;

EID: 33746210177     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.2015     Document Type: Article

References (44)

1. Whipple, G. H. 1907. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull. Johns Hopkins Hosp. 18: 382-393.
2. Relman, D. A., T. M. Schmidt, R. P. MacDermott, and S. Falkow. 1992. Identification of the uncultured bacillus of Whipple's disease. N. Engl. J. Med. 327: 293-301.
3. Dobbins, W. I. 1987. Whipple's Disease. Charles C. Thomas, Springfield.
4. Keinath, R. D., D. E. Merrell, R. Vlietstra, and W. O. Dobbins, 3rd. 1985. Antibiotic treatment and relapse in Whipple's disease: long-term follow-up of 88 patients. Gastroenterology 88: 1867-1873.
5. Maiwald, M., F. Schuhmacher, H. J. Ditton, and A. von Herbay. 1998. Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii). Appl. Environ. Microbiol. 64: 760-762.
6. Swartz, M. N. 2000. Whipple's disease-past, present, and future. N. Engl. J. Med. 342: 648-650.
7. Ehrbar, H. U., P. Bauerfeind, F. Dully, H. R. Koelz, and M. Allwegg. 1999. PCR-positive tests for Tropheryma whippelii in patients without Whipple's disease. Lancet 353: 2214.
8. Zinkemagel, A. S., R. Gmur, L. Fenner, A. Schaffner, G. Schoedon, and M. Schneemann. 2003. Marginal and subgingival plaque-a natural habitat of Tropheryma whippelii Infection 31: 86-91.
9. Maibach, R. C., F. Dutly, and M. Altwegg. 2002. Detection of Tropheryma whipplei DNA in feces by PCR using a target capture method. J. Clin. Microbiol. 40: 2466-2471.
10. Raoult, D., M. L. Birg, B. La Scola, P. E. Fournier, M. Enea, H. Lepidi, V. Roux, J. C. Piette, F. Vandenesch, D. Vital-Durand, and T. J. Marrie. 2000. Cultivation of the bacillus of Whipple's disease. N. Engl. J. Med. 342: 620-624.
11. Feurle, G. E., B. Dorken, E. Schopf, and V. Lenhard. 1979. HLA B27 and defects in the T-cell system in Whipple's disease. Eur J. Clin. Invest. 9: 385-389.
12. Dobbins, W. O., 3rd. 1981. Is there an immune deficit in Whipple's disease? Dig. Dis. Sci. 26: 247-252.
13. Marth, T., M. Roux, A. von Herbay, S. C. Meuer, and G. E. Feurle. 1994. Persistent reduction of complement receptor 3 α-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin. Immunol. Immunopathol. 72: 217-226.
14. Marth, T., N. Kleen, A. Stallmach, S. Ring, S. Aziz, C. Schmidt, W. Strober, M. Zeitz, and T. Schneider. 2002. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology 123: 1468-1477.
15. Marth, T., M. Neurath, B. A. Cuccherini, and W. Strober. 1997. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology 113: 442-448.
16. Kalt, A., T. Schneider, S. Ring, J. Hoffmann, M. Zeitz, A. Stallmach, D. H. Persing, and T. Marth. 2006. Decreased levels of interleukin-12p40 in the serum of patients with Whipple's disease. Int. J. Colorectal Dis. 21: 114-120.
17. Desnues, B., H. Lepidi, D. Raoult, and J. L. Mege. 2005. Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of m2/alternatively activated macrophages. J. Infect. Dis. 192: 1642-1646.
18. Schneider, T., R. Ullrich, C. Bergs, W. Schmidt, E. O. Riecken, and M. Zeitz. 1994. Abnormalities in subset distribution, activation, and differentiation of T cells isolated from large intestine biopsies in HIV infection. The Berlin Diarrhoea/Wasting Syndrome Study Group. Clin. Exp. Immunol. 95: 430-435.
19. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99: 1739-1750.
20. 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation. J. Immunol. 157: 1965-1972.
21. Marth, T., and D. Raoult. 2003. Whipple's disease. Lancet 361: 239-246.
22. Boulos, A., J. M. Rolain, and D. Raoult. 2004. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob. Agents Chemother. 48: 747-752.
23. Renesto, P., N. Crapoulet, H. Ogata, B. La Scola, G. Vestris, J. M. Claverie, and D. Raoult. 2003. Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 362: 447-449.
24. Kallas, E. G., D. C. Gibbons, H. Soucier, T. Fitzgerald, J. J. Treanor, and T. G. Evans. 1999. Detection of intracellular antigen-specific cytokines in human T cell populations. J. Infect. Dis. 179: 1124-1131.
25. Fenollar, F., H. Lepidi, R. Gerolami, M. Drancourt, and D. Raoult. 2003. Whipple disease associated with giardiasis. J. Infect. Dis. 188: 828-834.
26. + T cells specific for defined antigens according to CD154 expression. Nat. Med. 11:1118-1124.
27. Harari, A., F. Vallelian, P. R. Meylan, and G. Pantaleo. 2005. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174: 1037-1045.
28. Schneider, T., A. Stallmach, A. von Herbay, T. Marth, W. Strober, and M. Zeitz. 1998. Treatment of refractory Whipple disease with interferon-γ. Ann. Intern. Med. 129: 875-877.
29. Greenberg, S. B. 2002. Infections in the immunocompromised rheumatologic patient. Crit. Care Clin. 18: 931-934.
30. Samuel, R., R. L. Bettiker, and B. Suh. 2002. AIDS related opportunistic infections, going but not gone. Arch. Pharm. Res. 25: 215-228.
31. Ectors, N., K. Geboes, R. De Vos, H. Heidbuchel, P. Rutgeerts, V. Desmet, and G. Vantrappen. 1992. Whipple's disease: a histological, immunocytochemical and electronmicroscopic study of the immune response in the small intestinal mucosa. Histopathology 21: 1-12.
32. Belkaid, Y., and B. T. Rouse. 2005. Natural regulatory T cells in infectious disease. Nat. Immunol. 6: 353-354.
33. Boussiotis, V. A., E. Y. Tsai, E. J. Yunis, S. Thim, J. C. Delgado, C. C. Dascher, A. Berezovskaya, D. Roussel, J. M. Reynes, and A. E. Goldfeld. 2000. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105: 1317-1325.
34. + regulatory T cell activity in both humans and mice. J. Immunol. 172: 834-842.
35. Ortega, G., R. J. Robb, E. M. Shevach, and T. R. Malek. 1984. The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J. Immunol. 133: 1970-1975.
36. Desnues, B., M. Ihrig, D. Raoult, and J. L. Mege. 2006. Whipple's disease: a macrophage disease. Clin. Vaccine Immunol. 13: 170-178.
37. Gratchev, A., K. Schledzewski, P. Guillot, and S. Goerdt. 2001. Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol. Appl. Skin Physiol. 14: 272-279.
38. Desnues, B., D. Raoult, and J. L. Mege. 2005. IL-16 is critical for Tropheryma whipplei replication in Whipple's disease. J. Immunol. 175: 4575-4582.
39. Cruikshank, W. W., H. Kornfeld, and D. M. Center. 2000. Interleukin-16. J. Leukocyte Biol. 67: 757-754.
40. Theodore, A. C., D. M. Center, J. Nicoll, G. Fine, H. Kornfeld, and W. W. Cruikshank. 1996. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. 157: 1958-1964.
41. Della Bella, S., S. Nicola, I. Timofeeva, M. L. Villa, A. Santoro, and A. C. Berardi. 2004. Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood 104: 4020-4028.
42. Somech, R., N. Amariglio, Z. Spirer, and G. Rechavi. 2003. Genetic predisposition to infectious pathogens: a review of less familiar variants. Pediatr. Infect. Dis. J. 22: 457-461.
43. Agaisse, H., L. S. Burrack, J. A. Philips, E. J. Rubin, N. Perrimon, and D. E. Higgins. 2005. Genome-wide RNAi screen for host factors required for intracellular bacterial infection. Science 309: 1248-1251.
44. Taylor, G. A., C. M. Collazo, G. S. Yap, K. Nguyen, T. A. Gregorio, L. S. Taylor, B. Eagleson, L. Secrest, E. A. Southon, S. W. Reid, et al. 2000. Pathogen-specific loss of host resistance in mice lacking the IFN-γ-inducible gene IGTP. Proc. Natl. Acad. Sci. USA 97: 751-755.